arGentis Pharmaceuticals, LLC Signs Exclusive License Agreement with UTRF for Scleroderma Treatment

MEMPHIS, Tenn.--(BUSINESS WIRE)--arGentis Pharmaceuticals, LLC announced today an agreement with The University of Tennessee Research Foundation to license the intellectual property surrounding the use of solubilized type 1 native bovine collagen (CI) as a treatment for systemic sclerosis (SSc or systemic scleroderma) and other fibrosing diseases. The agreement gives arGentis the rights to the treatment as well as the processes involved in manufacturing the pharmaceutical product.